• Company
• AZ will withdraw its KRW 50 bil Forxiga from KOR mkt
• by Kim, Jin-Gu Dec 12, 2023 05:38am

• Policy
• MOHW agrees to review current prior authorization system
• by Lee, Jeong-Hwan Dec 12, 2023 05:38am

• Company
• Reimb at a halt for one-shot IRD drug Luxturna
• by Eo, Yun-Ho Dec 12, 2023 05:38am

• Policy
• Roche’s DLBCL treatment Columvi approved in Korea
• by Lee, Hye-Kyung Dec 11, 2023 05:02am

• Policy
• Pfizer conducts trial for its RSV drug sisunatovir in KOR
• by Lee, Hye-Kyung Dec 11, 2023 05:02am

• Company
• Taked’a new CMV drug Livtencity passes DREC review in 1 yr
• by Eo, Yun-Ho Dec 11, 2023 05:02am

• Company
• Trulicity sales fall 30%...affected by supply shortage
• by Kim, Jin-Gu Dec 11, 2023 05:02am

• Company
• Double-dose Trelegy Ellipta in reimb process for asthma
• by Eo, Yun-Ho Dec 11, 2023 05:02am

• Company
• Chong Kun Dang receives attention for its 'R&D potential'
• by Chon, Seung-Hyun Dec 8, 2023 05:28pm

• Company
• Gardasil dominates HPV vaccine mkt in KOR
• by Kim, Jin-Gu Dec 8, 2023 05:55am